CellPly S.r.l.

CellPly S.r.l. is an Italian deep-tech company based in Bologna that builds analytical tools for the discovery, development and quality control of cell therapies. Its stated mission is to streamline the development of next-generation cancer therapies by giving biopharma companies and research institutes a faster, more effective way to characterize the immune cells at the heart of advanced therapies. The company combines expertise across microfluidics, robotics, artificial intelligence, biology and immunology, and positions itself at the intersection of laboratory automation and single-cell immunology. CellPly's flagship offering is the VivaCyte platform, described by the company as a one-of-a-kind analytical system for discovery and process development of cell therapies. VivaCyte is a standalone, fully automated, end-to-end solution that integrates proprietary disposable microfluidic devices, an instrument for sample preparation and cell analysis, and software for workflow configuration and automated image analysis at single-cell resolution. According to CellPly, the platform can process more than 100 samples per run and more than 1,000 single cells per sample, with many assays performed per cell. The instrument brings cell incubation, liquid handling and high-content imaging into a single box, allowing users to compare up to 128 conditions per run, link phenotype and function at the single-cell level, and analyze tens of thousands of single immune cells within hundreds of thousands of miniaturized co-cultures. CellPly claims the automation delivers up to 90% less hands-on time, a 90% reduction in input sample size, and reproducible killing assays with a coefficient of variation below 20%. The company serves biopharma companies and research institutes across the cell therapy value chain, from discovery through R&D to quality control of advanced therapies. It maintains an operating office in Bologna and addresses customers through regional commercial contacts, including a dedicated contact for the US market and one for the EMEA and APAC markets. CellPly is a private company; its leadership team includes CEO Alex Jones, President Alessia Zanelli, co-founder and Chief Operating Officer Massimo Bocchi, Chief Technology Officer Andrea Faenza, Head of Biology Laura Rocchi, Chief Business Officer Priyanka Dutta Passecker, Business Development Manager for EMEA/APAC Marco Fadda, Financial Controller Francesca Gambardella, and Operations & PMO Manager Paola Poggi. A board of directors includes Alessia Zanelli, Massimo Bocchi, Alex Jones, Antonella Beltrame, Carmelo Catalano, Teresa De Nadai and Miro Venturi, and the company lists investors on its website. As a relatively young deep-tech venture, CellPly is best understood as a specialist instrumentation and consumables provider for the cell and gene therapy industry rather than a broad life-science conglomerate. Its differentiation rests on combining microfluidics, automation and AI-driven image analysis to compress experiment turnaround time and improve reproducibility for scientists developing immune-cell-based cancer treatments.

CellPly S.r.l. is a deep-tech company based in Bologna, Italy, focused on analytical tools for the development of cell therapies. Public information about the company is concentrated in its own website and a Wikidata entry that identifies it simply as a company in Bologna, Italy. The company was co-founded by Massimo Bocchi, who serves as Chief Operating Officer, and it has assembled a leadership team combining expertise in microfluidics, robotics, artificial intelligence, biology and immunology. From its operating office on Via Massarenti in Bologna, CellPly has built its business around a single flagship platform, VivaCyte, which it describes as a one-of-a-kind analytical system for discovery and process development of cell therapies. The platform was designed as a standalone, fully automated, end-to-end solution that integrates proprietary disposable microfluidic devices, an instrument for sample preparation and cell analysis, and software for workflow configuration and automated image analysis at single-cell resolution. CellPly states that VivaCyte enables characterization of immune cells at unprecedented resolution and scale, with more than 100 samples per run and more than 1,000 single cells per sample, and many assays per cell. The company's stated mission is to streamline the development of next-generation cancer therapies. It targets biopharma companies and research institutes, supporting them from discovery through R&D to quality control of advanced therapies. CellPly markets the VivaCyte platform as bringing an entire lab into a single box by integrating cell incubation, liquid handling and high-content imaging, and it emphasizes throughput and reproducibility benefits: comparison of up to 128 conditions per run, analysis of tens of thousands of single immune cells within hundreds of thousands of miniaturized co-cultures, up to 90% less hands-on time, a 90% reduction of input sample size, and reproducible killing assays with a coefficient of variation below 20%. CellPly operates as a private company. Its leadership includes CEO Alex Jones, President Alessia Zanelli, co-founder and COO Massimo Bocchi, CTO Andrea Faenza, Head of Biology Laura Rocchi, Chief Business Officer Priyanka Dutta Passecker, Business Development Manager for EMEA/APAC Marco Fadda, Financial Controller Francesca Gambardella, and Operations & PMO Manager Paola Poggi. Its board of directors includes Alessia Zanelli, Massimo Bocchi, Alex Jones, Antonella Beltrame, Carmelo Catalano, Teresa De Nadai and Miro Venturi. The company lists investors on its website and maintains commercial contacts for the US market and for the EMEA/APAC markets, indicating an international commercial orientation beyond its Italian base.

• CellPly is established as a deep-tech company in Bologna, Italy, co-founded by Massimo Bocchi.

• CellPly introduces VivaCyte as its flagship analytical platform for cell therapy discovery and process development.

• CellPly markets the VivaCyte platform with end-to-end automation, proprietary disposable microfluidic devices and automated single-cell image analysis.

Deep-tech provider of automated single-cell analysis platforms for cell therapy discovery, process development and quality control.

• VivaCyte platform

  Standalone, fully automated, end-to-end cell therapy characterization platform integrating proprietary disposable microfluidic devices, an instrument for sample prep and cell analysis, and software for workflow configuration and automated image analysis at single-cell resolution.

• VivaCyte instrument

  Standalone automated system that brings cell incubation, liquid handling and high-content imaging into a single box, enabling comparison of up to 128 conditions per run.

• Disposable microfluidic devices

  Proprietary consumables used within the VivaCyte platform for miniaturized co-cultures and single-cell analysis.

• Workflow and image analysis software

  Software for workflow configuration and automated image analysis at single-cell resolution.

1. 1Homepage | CELLPLYcellply.com
2. 2Products | CELLPLYcellply.com
3. 3About Us | CELLPLYcellply.com
4. 4CellPly S.r.l. (Italy) - Wikidatawikidata.org